BACKGROUND: This study evaluated the performance of the BD ProbeTec Chlamydia trachomatis Q (CTQ) Amplified DNA Assay on the BD Viper System with XTR Technology in a multicenter study. METHODS: Specimens were collected at 7 geographically diverse clinical sites from 1538 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1465 evaluable participants, 993 women and 472 men. CTQ assay results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens as well as those obtained using the Urine Preservative Transport (UPT) tube for the CTQ assay were compared with patient-infected status (PIS). PIS was determined based on the combined results from Aptima Combo 2 and BD ProbeTec ET CT Amplified DNA Assay. RESULTS: The sensitivity versus PIS for endocervical, vaginal, and both female urine samples was 91.3%, 96.5%, and 93.0%, respectively. The specificity for the same specimen types was 98.3%, 99.2%, and 99.4% (urine neat) and 99.2% (UPT), respectively. The sensitivity versus PIS for male urethral swabs and both male neat and UPT urine were 92.1% and 98%, respectively, with specificities of 98.4%, 99.2%, and 98.1%, respectively. CONCLUSIONS: The CTQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as Aptima Combo 2 and BD ProbeTec ET CT-Amplified DNA assay. Vaginal swabs and male urine specimens, the sample types recommended by the Centers for Disease Control for chlamydia screening, both performed at least as well as other sample types evaluated.
BACKGROUND: This study evaluated the performance of the BD ProbeTec Chlamydia trachomatis Q (CTQ) Amplified DNA Assay on the BD Viper System with XTR Technology in a multicenter study. METHODS: Specimens were collected at 7 geographically diverse clinical sites from 1538 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1465 evaluable participants, 993 women and 472 men. CTQ assay results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens as well as those obtained using the Urine Preservative Transport (UPT) tube for the CTQ assay were compared with patient-infected status (PIS). PIS was determined based on the combined results from Aptima Combo 2 and BD ProbeTec ET CT Amplified DNA Assay. RESULTS: The sensitivity versus PIS for endocervical, vaginal, and both female urine samples was 91.3%, 96.5%, and 93.0%, respectively. The specificity for the same specimen types was 98.3%, 99.2%, and 99.4% (urine neat) and 99.2% (UPT), respectively. The sensitivity versus PIS for male urethral swabs and both male neat and UPT urine were 92.1% and 98%, respectively, with specificities of 98.4%, 99.2%, and 98.1%, respectively. CONCLUSIONS: The CTQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as Aptima Combo 2 and BD ProbeTec ET CT-Amplified DNA assay. Vaginal swabs and male urine specimens, the sample types recommended by the Centers for Disease Control for chlamydia screening, both performed at least as well as other sample types evaluated.
Authors: Charlotte A Gaydos; Kimberly A Crotchfelt; Nina Shah; Marie Tennant; Thomas C Quinn; Joel C Gaydos; Kelly T McKee; Anne M Rompalo Journal: J Clin Microbiol Date: 2002-03 Impact factor: 5.948
Authors: A M Rompalo; C A Gaydos; N Shah; M Tennant; K A Crotchfelt; G Madico; T C Quinn; R Daniel; K V Shah; J C Gaydos; K T McKee Journal: Clin Infect Dis Date: 2001-09-24 Impact factor: 9.079
Authors: B Van Der Pol; T C Quinn; C A Gaydos; K Crotchfelt; J Schachter; J Moncada; D Jungkind; D H Martin; B Turner; C Peyton; R B Jones Journal: J Clin Microbiol Date: 2000-03 Impact factor: 5.948
Authors: Sally B Rose; Beverley A Lawton; Collette Bromhead; E Jane Macdonald; Kim A Lund Journal: Aust N Z J Obstet Gynaecol Date: 2007-10 Impact factor: 2.100
Authors: David H Martin; Malanda Nsuami; Julius Schachter; Edward W Hook; Dennis Ferrero; Thomas C Quinn; Charlotte Gaydos Journal: J Clin Microbiol Date: 2004-10 Impact factor: 5.948
Authors: C A Gaydos; T C Quinn; D Willis; A Weissfeld; E W Hook; D H Martin; D V Ferrero; J Schachter Journal: J Clin Microbiol Date: 2003-01 Impact factor: 5.948
Authors: Barbara Van Der Pol; Terri Warren; Stephanie N Taylor; Mark Martens; Keith R Jerome; Leandro Mena; Joel Lebed; Savita Ginde; Paul Fine; Edward W Hook Journal: J Clin Microbiol Date: 2012-08-08 Impact factor: 5.948
Authors: Johan H Melendez; Jill S Huppert; Mary Jett-Goheen; Elizabeth A Hesse; Nicole Quinn; Charlotte A Gaydos; Chris D Geddes Journal: J Clin Microbiol Date: 2013-06-26 Impact factor: 5.948
Authors: Jeanne Moncada; Carey B Clark; Jeffrey Holden; Edward W Hook; Charlotte A Gaydos; Julius Schachter Journal: J Clin Microbiol Date: 2017-01-11 Impact factor: 5.948
Authors: Barbara Van Der Pol; Stephanie N Taylor; William Lebar; Thomas Davis; Deanna Fuller; Leandro Mena; Paul Fine; Charlotte A Gaydos; David H Martin; Edward W Hook Journal: Sex Transm Dis Date: 2012-02 Impact factor: 2.830
Authors: Barbara Van Der Pol; James A Williams; DeAnna Fuller; Stephanie N Taylor; Edward W Hook Journal: J Clin Microbiol Date: 2016-12-28 Impact factor: 5.948
Authors: Alison Footman; Jodie Dionne-Odom; Kristal J Aaron; James L Raper; Barbara Van Der Pol Journal: Sex Transm Dis Date: 2020-03 Impact factor: 2.830
Authors: Emma R Liechty; Ingrid L Bergin; Christine M Bassis; Daniel Chai; William LeBar; Vincent B Young; Jason D Bell Journal: Pathog Dis Date: 2015-09-13 Impact factor: 3.166
Authors: Barbara Van Der Pol; James A Williams; Stephanie N Taylor; Catherine L Cammarata; Charles A Rivers; Barbara A Body; Melinda Nye; Deanna Fuller; Jane R Schwebke; Mathilda Barnes; Charlotte A Gaydos Journal: J Clin Microbiol Date: 2014-01-03 Impact factor: 5.948